Literature DB >> 17121850

In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation.

Xiulong Xu1, Geetha Rao, Roderick M Quiros, Anthony W Kim, Hua-Quan Miao, Gregory J Brunn, Jeffrey L Platt, Paolo Gattuso, Richard A Prinz.   

Abstract

Heparan sulfate proteoglycans (HSPGs) function as a co-receptor for heparin-binding growth factors, such as fibroblast growth factors (FGFs) and heparin-bound epidermal growth factor (HB-EGF). The HS side chain of HSPGs can be cleaved by HPR1 (heparanase-1), an endoglycosidase that is overexpressed in many types of malignancies. In the present study, we demonstrated that HPR1 expression in pancreatic adenocarcinomas inversely correlated with the presence of heparan sulfate (HS) in the basement membrane. In vitro cell culture study revealed that cell surface HS levels inversely correlated with HPR1 activity in five pancreatic cancer cell lysates and their conditioned media. Heparin and PI-88, two HPR1 inhibitors, were able to increase cell surface HS levels in PANC-1 cells in a dose-dependent manner. The ability of HPR1 to degrade cell surface HS was confirmed by showing that cell surface HS levels were increased in HT1080 cells stably transfected with the HPR1 antisense gene but was decreased in the cells overexpressing HPR1. Further studies showed that PI-88 and heparin were able to stimulate PANC-1 cell proliferation in the absence or presence of exogenous FGF2, whereas exogenous HPR1 was able to inhibit PANC-1 cell proliferation in a dose-dependent manner. Modulation of PANC-1 cell proliferation by HPR1 or HPR1 inhibitors corresponded with the inhibition or activation of the mitogen-activated protein kinase. Our results suggest that HPR1 expressed in pancreatic adenocarcinomas can suppress the proliferation of pancreatic tumor cells in response to the growth factors that require HSPGs as their co-receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121850     DOI: 10.1074/jbc.M604218200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation.

Authors:  Geetha Rao; Dingxie Liu; Mingzhao Xing; Jordi Tauler; Richard A Prinz; Xiulong Xu
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

2.  Method development and analysis of free HS and HS in proteoglycans from pre- and postmenopausal women: evidence for biosynthetic pathway changes in sulfotransferase and sulfatase enzymes.

Authors:  Wei Wei; Rebecca L Miller; Julie A Leary
Journal:  Anal Chem       Date:  2013-05-28       Impact factor: 6.986

3.  Heparan sulfate differences in rheumatoid arthritis versus healthy sera.

Authors:  Jenny K Sabol; Wei Wei; Marcos López-Hoyos; Youjin Seo; Armann Andaya; Julie A Leary
Journal:  Matrix Biol       Date:  2014-09-11       Impact factor: 11.583

4.  Extended N-sulfated domains reside at the nonreducing end of heparan sulfate chains.

Authors:  Gregory O Staples; Xiaofeng Shi; Joseph Zaia
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

5.  Tandem mass spectrometry of heparan sulfate negative ions: sulfate loss patterns and chemical modification methods for improvement of product ion profiles.

Authors:  Xiaofeng Shi; Yu Huang; Yang Mao; Hicham Naimy; Joseph Zaia
Journal:  J Am Soc Mass Spectrom       Date:  2012-07-24       Impact factor: 3.109

6.  Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis.

Authors:  G Rao; H G Ding; W Huang; D Le; J B Maxhimer; A Oosterhof; T van Kuppevelt; H Lum; E J Lewis; V Reddy; R A Prinz; X Xu
Journal:  Diabetologia       Date:  2011-03-20       Impact factor: 10.122

7.  High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF.

Authors:  Andreas-Claudius Hoffmann; Ryutaro Mori; Daniel Vallbohmer; Jan Brabender; Uta Drebber; Stephan E Baldus; Ellen Klein; Mizutomo Azuma; Ralf Metzger; Christina Hoffmann; Arnulf H Hoelscher; Kathleen D Danenberg; Klaus L Prenzel; Peter V Danenberg
Journal:  J Gastrointest Surg       Date:  2008-08-13       Impact factor: 3.452

8.  Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis.

Authors:  Madhuchhanda Roy; Dario Marchetti
Journal:  J Cell Biochem       Date:  2009-02-01       Impact factor: 4.429

9.  Two heparanase splicing variants with distinct properties are necessary in early Xenopus development.

Authors:  Gabriel E Bertolesi; George Michaiel; Sarah McFarlane
Journal:  J Biol Chem       Date:  2008-04-07       Impact factor: 5.157

10.  A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.

Authors:  Laura Q M Chow; Daniel L Gustafson; Cindy L O'Bryant; Lia Gore; Michele Basche; Scott N Holden; Mark C Morrow; Stacy Grolnic; Brian R Creese; Kaye L Roberts; Kat Davis; Russell Addison; S Gail Eckhardt
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-05       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.